Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - ReShape Lifesciences Inc. | obln-ex311_177.htm |
| 10-Q - 10-Q - ReShape Lifesciences Inc. | obln-10q_20160930.htm |
| EX-31.2 - EX-31.2 - ReShape Lifesciences Inc. | obln-ex312_178.htm |
| EX-10.7 - EX-10.7 - ReShape Lifesciences Inc. | obln-ex107_176.htm |
| EX-10.6 - EX-10.6 - ReShape Lifesciences Inc. | obln-ex106_175.htm |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Obalon Therapeutics, Inc. (the “Company”) for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew Rasdal, the President and Chief Executive Officer, and I, and William Plovanic, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 10, 2016
|
/s/ Andrew Rasdal |
|
/s/ William Plovanic |
|
Andrew Rasdal |
|
William Plovanic |
|
President and Chief Executive Office |
|
Chief Financial Officer |
|
(Principal Executive Officer) |
|
(Principal Financial Officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.